NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial-Reference-Cited by-同舟云学术

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial

Published:2018-06 Issue:6 Volume:19 Page:799-811
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gregorc Vanesa,Gaafar Rabab M,Favaretto Adolfo,Grossi Francesco,Jassem Jacek,Polychronis Andreas,Bidoli Paolo,Tiseo Marcello,Shah Riyaz,Taylor Paul,Novello Silvia,Muzio Alberto,Bearz Alessandra,Greillier Laurent,Fontana Floriana,Salini Giulia,Lambiase Antonio,O'Brien Mary

Publisher

Elsevier BV

Subject

Oncology

Reference39 articles.

1. Advances in malignant mesothelioma;Robinson;N Engl J Med,2005

2. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

3. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial;Zalcman;Lancet,2016

4. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma;Jassem;J Clin Oncol,2008

5. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial;Krug;Lancet Oncol,2015

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects;Current Cancer Therapy Reviews;2024-07-23

2. Evaluation of first-line and salvage therapies for unresectable malignant mesothelioma: A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-06

3. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice;Experimental Hematology & Oncology;2024-03-01

4. Cancer-specific glycosylation of CD13 impacts its detection and activity in preclinical cancer tissues;iScience;2023-11

5. Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma;Thoracic Cancer;2023-07-17